Handa Pharma
漢達生技醫藥股份有限公司
Handa Pharma is a Taiwan TPEx-listed biotechnology company; its most advanced asset is HND-039 (FDA final approval; launch preparation, Cancer), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| HND-039 | — | FDA final approval; launch preparation | Cancer | United States | 2026-09-04 | Company disclosure |
| HND-032 | — | — | — | — | 2025-05-22 | Company disclosure |
| HND-033 | — | — | — | — | 2025-09-19 | Company disclosure |
Key events
- HND-039: FDA final approval; launch preparation
Related Drugnews articles
No related articles in this language.